Germany - Drugs

Description

The purpose of this announcement is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 SGB V. The invitation to participate is only addressed to pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act. It is not an open procedure pursuant to Section 15 VgV in conjunction with Section 119 (3) GWB, but a publication of the invitation to conclude/join discount agreements with terms and conditions that are fixed and non-negotiable for all participants, including the amount of the discount. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act may become contracting parties.
The purpose of this notice is to conclude agreements on the active ingredient "Alendronic acid, colecalciferol (ATC code: M05BB03) pharmaceutical form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Ambroxol - available only on the pharmacy shelf (ATC code: R05CB06) pharmaceutical form: LOE, LSE, SAF, SIR, TRO, drip solution, TEI" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Amoxicillin (ATC code: J01CA04) pharmaceutical form: GSE, PSE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Atazanavir (ATC code: J05AE08) pharmaceutical form: HKP" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) pharmaceutical form: CRE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) Dosage form: EMU" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) pharmaceutical form: LOE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only at pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) pharmaceutical form: SAL" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone, salicylic acid (ATC code: D07XC01) pharmaceutical form: SAL" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Calcium carbonate, colecalciferol (ATC code: A12AX) pharmaceutical form: BTA, FTA, KTA, effervescent granules" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Clopidogrel, acetylsalicylic acid (ATC code: B01AC30) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "colistimethate natrium (ATC code: J01XB01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Cyanocobalamin - available only on prescription (ATC code: B03BA01) pharmaceutical form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Cyproterone acetate, ethinyl estradiol (ATC code: G03HB01) pharmaceutical form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Desogestrel, Ethinylestradiol (ATC code: G03AA09) Dosage form: FTA, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Drospirenone, Ethinylestradiol (ATC-Code: G03AA12) Dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Drospirenone (ATC code: G03AC10) Dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Estriol (ATC code: G03CA04) pharmaceutical form: VCR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "famotidine (ATC code: A02BA03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Fluorouracil - against warts, salicylic acid (ATC code: L01BC52)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Flupentixol (ATC code: N05AF01) pharmaceutical form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Gefitinib (ATC code: L01EB01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Ibuprofen (ATC code: M01AE01) pharmaceutical form: REK, RET, sustained release film-coated tablet, SL sustained release capsule" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Ibuprofen (ATC code: M01AE01) pharmaceutical form: SUE, SIR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "isosorbide dinitrate (ATC code: C01DA08) pharmaceutical form: RED, REK, RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "isosorbide dinitrate (ATC code: C01DA08) pharmaceutical form: SUT, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "isosorbide mononitrate (ATC code: C01DA14) pharmaceutical form: RED, REK, RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "isosorbide mononitrate (ATC code: C01DA14) pharmaceutical form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Ivermectin (ATC code: P02CF01) pharmaceutical form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Metamizole (ATC code: N02BB02) pharmaceutical form: AMP, ILO, INF" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Methyldopa (ATC code: C02AB01) Dosage form: FTA, TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Metoclopramide (ATC code: A03FA01) pharmaceutical form: LSE, TEI, LOE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Metoprolol succinate, hydrochlorothiazide (ATC code: C07BB02) pharmaceutical form: RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is September 5, 2025. In any case, the contracts will end on October 31, 2025. This announcement serves to conclude agreements on the active ingredient "Montelukast (ATC code: R03DC03) pharmaceutical form: GRA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is September 5, 2025. In any case, the contracts will end on October 31, 2025. This announcement serves to conclude agreements on the active ingredient "Montelukast (ATC code: R03DC03) Dosage form: KTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Morphine (ATC code: N02AA01) pharmaceutical form: AMP, ILO, INF" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Mupirocin (ATC code: R01AX06) pharmaceutical form: NSA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "Natalizumab (ATC code: L04AA23) pharmaceutical form: IFK" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Octreotide (Depot) (ATC code: H01CB02) Dosage form: TRS, DFL" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Posaconazole (ATC code: J02AC04) pharmaceutical form: SUE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Salbutamol (ATC code: R03AC02) Dosage form: LOV - ready-to-use inhalate" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Salmeterol (ATC code: R03AC12) pharmaceutical form: DOS" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Sapropterin (ATC code: A16AX07) pharmaceutical form: PLE, TLE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Teriflunomide (ATC code: L04AA31) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Teriparatide (ATC code: H05AA02) pharmaceutical form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Xylometazoline (ATC code: R01AA07) pharmaceutical form: EDP, NDS, NSG, NAG, NTR, nasal solution" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "ranolazine (ATC code: C01EB18) pharmaceutical form: RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Fingolimod (ATC code: L04AA27) pharmaceutical form: HKP" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Ganirelix (ATC code: H01CC01) pharmaceutical form: IFE, ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. The purpose of this announcement is to conclude agreements on the active ingredient "tocilizumab (ATC code: L04AC07)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025. This announcement serves to conclude agreements on the active ingredient "rotigotine (ATC code: N04BC09) pharmaceutical form: PFT" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de to the CAB.Earliest start of the contract is 01.11.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.10.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The deadline for receipt of accessions is 05.09.2025. In any case, the contracts end on 31.10.2025.

Opportunity closing date

05 September 2025

Value of contract

to be confirmed